Virtuoso Therapeutics to Present Preclinical Findings on Three Best-in-Class Bispecific and ADC Programs at the 2023 American Association for Cancer Research (AACR) Annual Meeting
11 Apr 2023
AACRImmunotherapy
SAN MATEO, Calif., April 11, 2023 /PRNewswire/ -- Virtuoso Therapeutics, Inc., a private oncology-focused company developing novel bispecific antibodies today announced that it will present three posters highlighting the preclinical data from leading bispecific antibody and ADC programs at the American Associate for Cancer Research (AACR) 2023 Annual Meeting.
The details of the Company's presentations at the AACR are as follows:
Poster Presentation #1870:
Title: VBI–003, a CD47xEpCAM bispecific antibody as a potential treatment for colorectal and small cell lung cancers
Session Category: Immunology
Session Title: Therapeutic Antibodies 1
Presenting Author: Oi Kwan Wong, Ph.D., Senior Director, Translational Biology
Date/Time: April 17th 9:00AM-12:30PM
Location: Section 25
Poster Presentation #6334:
Title: VBI-002, a CD47xICAM-1 bispecific antibody for the treatment of hepatocellular carcinoma, melanoma and non-small cell lung cancers
Session Category: Immunology
Session Title: Anticancer Immunotherapeutics
Presenting Author: Oi Kwan Wong, Ph.D., Senior Director, Translational Biology
Date/Time: April 19th 9:00AM-12:30PM
L
ocation: Section 22
Poster Presentation #6298:
Title: A novel topoisomerase I inhibitor based anti-ICAM–1 antibody drug conjugate for the treatment of hematologic malignancies and solid tumors
Session Category: Experimental and Molecular Therapeutics
Session Title: Growth Factor Receptors as Therapeutic Targets
Presenting Author: Oi Kwan Wong, Ph.D., Senior Director, Translational Biology
Date/Time: April 19th 9:00AM-12:30PM
L
ocation: Section 21
"We believe that our best-in-class CD47 bispecific antibodies confer greater tumor selectivity without sacrificing potency and efficacy. They have been optimized and are ready to begin IND enabling studies," said Sofie Qiao, PhD, President and CEO of Virtuoso Therapeutics. Posters will be available at www.virtuosotherapuetics.com after the meeting.
Virtuoso Therapeutics is an oncology-focused company developing novel bispecific antibodies. The team's expertise and insights could address some of the fundamental challenges of these modalities, such as efficacy and therapeutic window. By applying Virtuoso's technology and know-how, the bispecific programs are highly differentiated and have the potential to achieve a unique product profile.
For more information, please visit www.virtuosotherapeutics.com.
Contact Information
Sofie Qiao, Ph.D.
President and CEO
[email protected]
650.666.2753
SOURCE Virtuoso Therapeutics
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.